Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report | Zendy

Xinying Xue | Zendy; Qingliang Xue | Zendy; Yuxia Liu | Zendy; Lei Pan | Zendy; Kaifei Wang | Zendy; Lina Zhang | Zendy; Na Wang | Zendy; Bing Yang | Zendy; Wang Jian-xin | Zendy

Open Access

Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report

Author(s) -

Xinying Xue,

Qingliang Xue,

Yuxia Liu,

Lei Pan,

Kaifei Wang,

Lina Zhang,

Na Wang,

Bing Yang,

Wang Jian-xin

Publication year - 2013

Publication title -

oncology letters

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.766

H-Index - 54

eISSN - 1792-1082

pISSN - 1792-1074

DOI - 10.3892/ol.2013.1212

Subject(s) - gefitinib , medicine , lung cancer , interstitial lung disease , prednisolone , oncology , adverse effect , cancer , lung , epidermal growth factor receptor

Gefitinib-induced interstitial lung disease (ILD) is a rare but lethal drug adverse event, which usually leads to the withdrawal of gefitinib and causes complications with anticancer treatment. In this study, gefitinib administration combined with prednisolone in a female with stage IIIb non-small cell lung cancer (NSCLC) produced a good outcome without inducing ILD. The results suggested that combined administration of gefitinib with glucocorticoids may be an efficient method to treat NSCLC while avoiding complications with ILD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research